Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Following the spin-off of its Sandoz generics division in 2023 and the Alcon eye-care division in 2019, the company operates as a pure-play innovative medicines business. Novartis focuses on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. The company's product portfolio includes notable drugs such as Entresto, Cosentyx, Kisqali, and Kesimpta. Novartis invests heavily in research and development, advancing emerging technology platforms like gene and cell therapy, radioligand therapy, and xRNA. The company generates revenue globally, with significant sales in the United States, Europe, and emerging markets.
